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Abstract
Background: Prolonged electrocardiogram QRS durations are often present in hypertensive patients. Small
increases in QRS duration serve as independent risk factors for both increased cardiovascular and all-cause mortality.
Aortic stiffness is associated with increases in central aortic systolic blood pressure (CASP). However CASP and ECG
QRS duration interactions have not been established in rural community populations. Our aims are to determine if
QRS duration > 100 msec is associated with an elevated CASP measure in an Australian rural population.
Methods: A retrospective cross sectional population was obtained from the CSU Diabetes Screening Research
Initiative data base where 68 participants had both central aortic pressure recorded and ECG derived QRS duration.
Central aortic pressure was determined by directly recording radial arterial tonometry and brachial cuff pressure
(HealthStats, Singapore). Resting 12-lead electrocardiograms were obtained from each subject using a Welch Allyn
PC-Based ECG system.
Results: The population had a mean CASP of 137.8 mmHg, higher than previously reported in other population studies.
In 8/68 subjects with a prolonged cardiac QRS duration >120 msec, CASP ranged from 129 mmHg – 182 mmHg. When
subgroup analysis was stratified on the basis QRS duration <100 msec and ≥100 msec significant differences (p = 0.036)
were observed for mean CASP, 130.6 mmHg± 15.6 (SD) versus 140.6 mmHg± 16.8 (SD), respectively.
Conclusions: Our results suggest that an arbitrary CASP reading greater than a value 140 mmHg raises suspicion of a
prolonged QRS duration. QRS durations ≥100 msec in an aging rural population are associated with higher CASP
measures. Our results also suggest in aging Australian rural populations CASP is likely to be elevated, possibly due to age
related aortic stiffening.
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Background
Electrocardiogram (ECG) derived QRS durations >100 msec
and >120 msec have been both associated with hyperten-
sion induced increases in left ventricular (LV) mass [1–4].
Myocardial hypertrophy can alter LV tissue repolarisation
and slowing of transmural conduction velocity [5, 6]. Slo-
wed conduction of electrical impulses through the cardiac
ventricles is marked by increases in QRS duration [6].
Cardiac hypertrophy may be associated with impaired cor-
onary vasodilator reserve, decreased capillary density, re-
duced connexin-43 expression, and increased individual
cardiac myocyte cell diameter, all of which can result in slo-
wed conduction velocity [7, 8].
The pathology of LVH (left ventricular hypertrophy)
can be associated with increased central systolic pressure
and is related to aortic stiffness [9, 10]. Aortic stiffness
has been shown across various models and human pop-
ulations to increase cardiac afterload and reduce
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coronary vasodilator reserve [11]. Persistent increases in
cardiac afterload can result in cardiac hypertrophic sig-
nalling and reduced coronary perfusion. Increased car-
diac mass and cardiac cellular structural and electrical
remodelling as a result of increased aortic stiffening
would theoretically predict an increase in QRS duration
associated with developed cardiac hypertrophy [1, 12].
Aortic elastic properties are relevant to increases in
central aortic systolic pressures, particularly aortic stiff-
ening. The aorta has an elastic buffering component
often referred to as a Windkessel [10]. That is the aorta
can store about 50 % of the left ventricular stroke vol-
ume during systole. In diastole, the stored volume is re-
leased from the elastic forces of the aortic wall to assist
peripheral circulation [10]. The elastic resistance (or
stiffness), increases with aging [12, 13], with an increase
in systolic central and peripheral blood pressure [10].
Chronic stiffness of large conduit vessels can lead to car-
diac hypertrophy [2, 14].
On the basis of ventricular-aortic coupling, central aor-
tic systolic pressure (CASP) has emerged as a more accur-
ate predictor of cardiovascular structural hypertrophy
than brachial pressures and pulse pressures [15]. Pressure
in the brachial artery differs from pressure in the ascend-
ing aorta due to amplification as the pressure pulse tran-
sits from central to peripheral arteries [15]. Clinically,
peripheral pressures do not always reflect central aortic
systolic stiffening [15, 16]. Importantly, the degree of amp-
lification is not fixed. CASP varies between individuals de-
pending upon age, cardiovascular disease and/or drug
therapy [15–17]. Central aortic pressure may be derived
non-invasively by accurate registration, capture and cali-
bration of a peripheral artery pressure waveform using an
externally applied arterial sensor with or without a bra-
chial pressure cuff reading [16]. The captured pressure
waveform undergoes mathematical transformations to de-
rive central aortic pressure, the validity of these processes
having been established during direct invasive catheter
measurements of the ascending aorta [17].
Considering the pathological implications for increased
aortic stiffness and impaired ventricular aortic coupling, it
would be logical to suggest that increased central aortic sys-
tolic pressure would be associated with increased QRS dur-
ation. However, to date there have been no studies in the
literature exploring this association in a patient series using
a CASP device. Our present study explores differences in
ECG derived QRS duration in 68 rural subjects with and
without type 2 diabetes and with and without hypertension.
Interactions with age and CASP are modelled as factors
that could influence prolonged QRS duration.
Methods
Human ethics clearance was obtained from Charles Stu-
art University (CSU) and written informed consent from
the patients involved in the present study. A retrospect-
ive cross sectional population was obtained from the
CSU Diabetes Screening Research Initiative (DiScRi)
data base where 68 participants had both central aortic
pressure recorded and ECG derived QRS duration. Sub-
jects were excluded if pregnant, non-ambulatory, cogni-
tively impaired, or had a history of heart failure. Two
blood pressure (BP) readings at the upper arm were
taken with the patient in a supine position, after resting
for 30 min, and the average recorded. Central aortic
pressure was determined using A-PULSE CASPro®, by
directly recording radial arterial tonometry and brachial
cuff pressure (HealthStats, Singapore) [15]. The A-
PULSE CASPro® algorithm for determining CASP has
been previous validated, for example a comparison made
of CASP estimated with the B-Pro device and Sphygmo-
Cor (as the “gold standard” reference device) in 104
healthy Caucasians demonstrated an correlation coeffi-
cient (r = 0.937) [18]. There is also excellent agreement
(r2 = 0.98, p < 0.001) between directly measured aortic
root systolic pressures using a Millar’s catheter at cardiac
catheterization versus NPMA-CASP HeathSTATS algo-
rithm [15].
Resting 12-lead electrocardiograms were obtained
from each subject using a Welch Allyn PC-Based ECG
system as previously described [4]. This permitted auto-
mated QRS duration calculation from a 10 s ECG trace.
Statistics were presented as means and standard devi-
ation (SD); Pearson product–moment correlation ana-
lysis and regression analysis was used to explore age
interactions with CASP and QRS duration. Statistical
significance was defined as p < 0.05.
Results
The demographics for the 68 subjects are shown in
Table 1. The mean age was 69.4 years and 8 subjects out
of 68 subjects had QRS durations greater than 120 msec.
Mean CASP levels for the study population were
138 mmHg ± 17 mmHg. The data was divided on pa-
tients self-reporting being hypertensive or not. Those di-
agnosed with hypertension were being treated. The
consequences of being treated or not being treated with
hypertension medications revealed no significant differ-
ences for mean QRS duration (104 ± 17 msec vs 107 ±
15 msec (BP treated) or mean CASP levels (134 ±
20 mmHg vs 139 ± 14 mmHg (BP treated).
Pearson’s correlation analysis showed a modest but sig-
nificant association between QRS duration and CASP (r=
0.25; p = 0.039). Both QRS duration (r= 0.25; p = 0.043)
(Fig. 1) and CASP (r= 0.41; p = 0.001) (Fig. 2) had a signifi-
cant but modest association with age. When we stratified
subpopulations on the basis of QRS duration <100 msec
and ≥100 msec significant differences (p = 0.036) were
observed for mean CASP, 130.6 ± 15.6 (SD) versus
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140.6 ± 16.8 (SD), respectively. The mean CASP in subjects
with a QRS duration > 120 msec was 145.25 mmHg±
14.9(SD). Of the subjects with a QRS duration >120 msec
only 1 subject had a QRS duration less than 130 msec, and
4/8 subjects had a QRS duration >140 msec. Current
guidelines have defined a suspicion for left bundle branch
block (LBBB) using a QRS duration of ≥130 msec in
women and a QRS duration of ≥ 140 msec in men [19].
Four subjects met the definition for suspicion of LBBB. The
average CASP for these 4 cases was 148 ± 14 mmHg. When
these 4 suspected LBBB cases were removed, the statistical
difference in mean CASP stratified on the basis of QRS
duration <100 msec (130.6 ± 15.6 mmHg) and ≥100 msec
(140 ± 14 mmHg) was not significant at p = 0.051.
Discussion and conclusions
In previous published population studies with age ranges
40 - 65 we have noted a median CASP of 115 mmHg [9].
We arbitrarily set a conservative CASP cut-off of 110 mm/
Hg as being within normal limits for healthy aging indi-
viduals [10]. Therefore, we defined a CASP >110 mmHg as
being abnormal. The mean CASP for our cohort was
137.8 mmHg – only 3/68 subjects in our cohort had a
CASP less than 110 mm/Hg (Table 1). When we ex-
plored CASP readings in the 8 subjects with a QRS
duration >120 msec we found that the mean CASP to
be 145 mm/Hg (range 127–167 mmHg) (Table 2).
Four cases with QRS duration > 120 msec were associ-
ated with LBBB risk using the QRS duration cut-offs de-
scribed in the Strauss criteria [19]. We did not have
access to the original ECG traces, only the automated
QRS durations for retrospective analysis, thus mid-QRS
notching in the leads to confirm LBBB using the Strauss
criteria were not available [19]. On the other hand we
question whether LBBB was present, given that CASP
Table 1 Population demographics and summary statistics
Total cohort (N = 68)
N or mean (SD) %





Cardiovascular disease 12 18.8
Diabetes 22 32.4
BMI 27.9 (4.6)
QRS (ms) 106.3 (15.7)
< 120 59 88.1
> 120 8 11.9
Peripheral SBP (mmHg) 133.5 (16.4)
< 110 4 5.9
> 110 64 94.1
< 120 13 19.1
> 120 55 80.9
Peripheral DBP (mmHg) 77 (8.4)
CASP (mmHg) 137.8 (17.2)
< 110 4 5.9
> 110 64 94.1
Central SBP (mmHg) 146.1 (17.5)
Central DBP (mmHg) 85.9 (10.2)
Central PP (mmHg) 101.3 (10.7)
CASP central aortic systolic pressure, SD standard deviation
Fig. 1 Scatter plot of subjects Age and QRS duration. The regression line is shown in blue; regression analysis R-Sq = 6.2 %; p = 0.043
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was elevated for each case. For example, one case study
of interment LBBB, when compared to normal conduc-
tion, LBBB was associated with a 20 mmHg decline in
systolic pressures in the left ventricle, central aorta and
radial artery [20].
CASP increases by approximately 3–4 mmHg per dec-
ade of life [15], while the difference between our cohort
overall and those patients with a prolonged QRS was esti-
mated to be double this value at 7 mmHg per decade of
life. Our findings demonstrate that in an Australian aging
rural population, mean CASP are greater (138 mmHg)
than those reported in other published community studies
with mixed healthy and chronic cardiovascular disease
participants (115–130 mmHg) [21–23]. However, the
mean CASP for our mixed population (138 mmHg) are
not dissimilar to central aortic systolic pressures reported
in patients undergoing cardiac catheter coronary interven-
tions (139.6 ± 1.4 mmHg) [24]. Surprisingly, despite the
mean CASP in our mixed, aging, rural population being
higher than previous studies, elevated CASP in our aging
cohort were rarely associated with an increase in QRS
width greater than 120 msec. We observed no differences
in QRS durations in those being treated for diagnosed
hypertension and those not being treated (i.e. subjects
without known hypertension).
Like most Australian rural populations, patients are
medically undertreated for blood pressure or are non
compliant with therapy. Previously, we have identified a
low usage of ACE inhibitors in the rural area of Albury
[25]. ACE inhibitors have been shown to reduce aortic
stiffening, independent of their blood pressure lowering
effects [26]. We suggest that blood pressure medication
other than ACE inhibitors may have favourably influ-
enced ventricular remodelling. For example, it has been
shown that that carvedilol results in a favourable pulse
pressure amplification and augmentation index by in-
creasing arterial compliance and reducing the magnitude
of wave reflection in hypertension [27]. Our cohort was
older (median 70 years) than previous published data on
median CASP levels and this may explain in part why
our mean CASP levels were higher than in previous
reports.
Additionally our aging cohort would have other in-
flammatory chronic conditions that would also in-
crease vascular stiffness [28–30]. We suggest because
of the likely higher burden of inflammatory conditions
Fig. 2 Scatter plot of subjects CASP and AGE. Regression line is shown in blue; regression analysis R-Sq = 13.4 %; p = 0.003
Table 2 Summary data for 8 subjects QRS > 120 msec
Total cohort (n = 8)
N or mean (SD) %







BMI (median, range) 29.6 (4.9)
Peripheral SBP (mmHg) 143.5 (11.2)
> 110 8 100
Peripheral DBP (mmHg) 82.4 (5.3)
CASP (mmHg) 145 (14.9)
> 110 8 100
Central SBP (mmHg) 154.3 (18.4)
Central DBP (mmHg) 89.6 (8.4)
Central PP (mmHg) 106.6 (8.4)
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associated with more advanced aging, it is not surpris-
ing to find an elevated CASP in our cohort.
We acknowledge our sample size was small and there-
fore, the validity of the signal averaged ECG QRS dur-
ation in association with CASP needs to be verified in a
larger study. Our study is cross-sectional in design and
therefore we are careful not to infer causality. In sum-
mary, our results suggest that an arbitrary CASP reading
greater than a value 140 mmHg raises suspicion of a
prolonged QRS duration >120mesc. QRS durations
≥100 msec in an aging rural population are associated
with higher CASP measures. Our results also suggest in
aging Australian rural populations CASP is likely to be
elevated, possibly due to age related aortic stiffening [30]
and increased CASP does not always equate with a pro-
longed QRS duration.
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